Experimental drug combo targets Hard-to-Treat pancreatic cancer
NCT ID NCT04158635
First seen Apr 25, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This early-stage trial tests whether adding the drug bosentan to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with pancreatic cancer that cannot be removed by surgery. The study involves 21 adults and aims to find the best dose of bosentan while monitoring side effects. Researchers hope this combination may slow or stop tumor growth better than chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PANCREATIC CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bosentan (a drug that blocks the hormone endothelin) combined with chemotherapy drugs gemcitabine and nab-paclitaxel
What this could lead to
If it works, this could point toward a new combination treatment to help control advanced pancreatic cancer that cannot be surgically removed.
What could go wrong
This is a very early Phase 1 trial with only 21 participants, focused on safety and dosing. The study is currently suspended, and it is unknown if the combination will improve outcomes or cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.